From :	Sebastian-A Molineus <smolineus@worldbank.org>
To :	Ekaterine Tikaradze <etikaradze@moh.gov.ge>; tgabunia@moh.gov.ge; i.matchavariani@mof.ge
Subject :	RE: Weekly Vaccine Marketplace Update as of 11 March, 2021 - with attachment
Cc :	Tania Dmytraczenko <tdmytraczenko@worldbank.org>; Ahmet Levent Yener <alyener@worldbank.org>; Volkan Cetinkaya <vcetinkaya@worldbank.org>; Nino V. Moroshkina <nmoroshkina@worldbank.org>
Received On :	12.03.2021 04:15
Attachments :	Vaccine Marketplace Update - as at 03-11-21.pptx Picture (Device Independent Bitmap) 1.jpg Picture (Device Independent Bitmap) 2.jpg Picture (Device Independent Bitmap) 3.jpg Picture (Device Independent Bitmap) 4.jpg

Dear Tamar – it was a pleasure meeting last night to help answer some of your questions on vaccine purchasing strategy. As discussed, we are putting you in touch with the authorities in Ukraine (for their experience with Crown), as well as the UAE (re. Sinopharm), and Armenia (to discuss possibly pooling, e.g. with respect to NOVOVAX, where I’d like to again highlight our advice to strike early, fast, and at great bulk!). On NOVOVAX, please note that they just released their updated results last night (see https://ir.novavax.com/node/15656/pdf), and they are: 96.4% effective against mild disease; 100% effective against hospitalizations; and 100% effective against death. Again, you may wish to move quickly on this and purchase larger quantities given the first mover advantage we discussed last night!

And attached is this week’s vaccine marketplace update – shared with you on a confidential basis. Of note is that Italy approved the AstraZeneca vaccine for over-65s, following a number of other European nations reversing their previous decisions to not use the vaccine for people over-65, including France and Germany.

Thank you and kind regards,

Sebastian

Sebastian Molineus
Regional Director for the South Caucasus

Europe and Central Asia
T +995 (32) 291 6238
M +995 (577) 78 7821
M +1 (202) 492-3914
E smolineus@worldbank.org
W www.worldbank.org/en/region/eca

@smolineus

www.linkedin.com/in/molineus/

_____________________________________________
From: Sebastian-A Molineus
Sent: Sunday, March 7, 2021 2:27 PM
To: Ivane Matchavariani (i.matchavariani@mof.ge) ; Ekaterine Tikaradze ; Tamar Gabunia
Cc: Tania Dmytraczenko ; Ahmet Levent Yener ; Volkan Cetinkaya ; Nino V. Moroshkina
Subject: Weekly Vaccine Marketplace Update as of 4 March, 2021 - with attachment

<< File: Vaccine Marketplace Update - as at 03-04-21.pptx >>

Dear Ivane, Eka, and Tamar -

please find attached the weekly vaccine marketplace update. A few highlights:

Johnson and Johnson was approved by the FDA. This is the first single dose vaccine to be approved by an SRA. It is considered a game changer within the USA because it is the first non-mRNA vaccine which means it can be stored and transported at normal freezer temperatures.

COVAX is starting to gain steam. Ghana, Ivory Coast, South Korea, India and Colombia have already received their first deliveries of vaccines through Covax. Nigeria, Angola, Cambodia all received their first vaccine doses via Covax this week, with the DR Congo also scheduled for a delivery. And this of course now also includes Georgia!

The EU is considering switching to Emergency Use approvals. Under pressure to speed up its approval process, The European Commission said that it was considering emergency approvals for COVID-19 vaccines as a faster alternative to more rigorous conditional marketing authorizations which have been used so far.

In terms of Vaccinations; more than 271 million doses (Last week: 218 million) have been administered across 108 countries (Last week: 99 countries), according to data collected by Bloomberg. The latest rate was roughly 6.36 million doses a day (Last week: 6.14 million doses a day).